Shaping of tumor and drug-resistant genomes by instability and selection

被引:60
作者
Snijders, AM
Fridlyand, J
Mans, DA
Segraves, R
Jain, AN
Pinkel, D
Albertson, DG
机构
[1] Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA
关键词
genetic instability; amplification; array CGH; mismatch repair;
D O I
10.1038/sj.onc.1206482
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tumors with defects in mismatch repair (MMR) show fewer chromosomal changes by cytogenetic analyses than most solid tumors, suggesting that a greater proportion of the alterations required for malignancy occur in genes with nucleotide sequences susceptible to errors normally corrected by MMR. Here, we used genome-wide microarray comparative genomic hybridization to carry out a higher resolution evaluation of the effect of MMR competence on genomic alterations occurring in 20 cell lines and to determine if characteristic aberrations arise in MMR-proficient and -deficient HCT116 cells undergoing selection for methotrexate resistance. We observed different spectra of aberrations in MMR-proficient compared to -deficient cell lines, as well as among cell lines with different types of MMR-deficiency. We also observed different genetic routes to drug resistance. Resistant MMR-deficient cells most frequently displayed no copy number alterations (16/29 cell pools), whereas all MMR-proficient cells had unique abnormalities involving chromosome 5, including amplicons centered on the target gene, DHFR and/or a neighboring novel locus (7/13 pools). These observations support the concept that tumor genomes are shaped by selection for alterations that promote survival and growth advantage, as well as by the particular dysfunctions in genes responsible for maintenance of genetic integrity.
引用
收藏
页码:4370 / 4379
页数:10
相关论文
共 51 条
[11]   Chromosome number and structure both are markedly stable in RER colorectal cancers and are not destabilized by mutation of p53 [J].
Eshleman, JR ;
Casey, G ;
Kochera, ME ;
Sedwick, WD ;
Swinler, SE ;
Veigl, ML ;
Willson, JKV ;
Schwartz, S ;
Markowitz, SD .
ONCOGENE, 1998, 17 (06) :719-725
[12]   Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes [J].
Esteller, M .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (18) :2294-2300
[13]  
Fink D, 1998, INT J CANCER, V77, P741, DOI 10.1002/(SICI)1097-0215(19980831)77:5<741::AID-IJC13>3.0.CO
[14]  
2-4
[15]   Different effects of methotrexate on DNA mismatch repair proficient and deficient cells [J].
Frouin, I ;
Prosperi, E ;
Denegri, M ;
Negri, C ;
Donzelli, M ;
Rossi, L ;
Riva, F ;
Stefanini, M ;
Scovassi, AI .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (09) :1173-1180
[16]  
Guan XY, 1996, CANCER RES, V56, P3446
[17]  
HAWN MT, 1995, CANCER RES, V55, P3721
[18]   A role for common fragile site induction in amplification of human oncogenes [J].
Hellman, A ;
Zlotorynski, E ;
Scherer, SW ;
Cheung, J ;
Vincent, JB ;
Smith, DI ;
Trakhtenbrot, L ;
Kerem, B .
CANCER CELL, 2002, 1 (01) :89-97
[19]   p53 regulates a G2 checkpoint through cyclin B1 [J].
Innocente, SA ;
Abrahamson, JLA ;
Cogswell, JP ;
Lee, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (05) :2147-2152
[20]   Fully automatic quantification of microarray image data [J].
Jain, AN ;
Tokuyasu, TA ;
Snijders, AM ;
Segraves, R ;
Albertson, DG ;
Pinkel, D .
GENOME RESEARCH, 2002, 12 (02) :325-332